Now Playing
News|Videos|October 13, 2023
Evolution of Advanced HER2+ Breast Cancer Management
Author(s)Jane L. Meisel, MD
Jane Meisel, MD, highlights how recent advancements in HER2+ advanced breast cancer treatments such as the introduction of tucatinib and trastuzumab deruxtecan are transforming patient care, particularly for those with brain metastases.
Advertisement
Episodes in this series
Advertisement
Related to this article
Camizestrant plus palbociclib did not significantly improve progression-free survival vs anastrozole plus palbociclib in the first-line SERENA-4 trial.
A UCLA-led review found there is not yet enough real-world evidence to determine whether using AI in routine screening actually reduces the number of breast cancers diagnosed between screenings
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
Advertisement
Advertisement
Trending on OncLive
1
DESTINY-Lung04 Showcases PFS Benefit With First-Line T-DXd in HER2-Mutant NSCLC
2
Adjuvant Osimertinib Keeps OS Benefit at 8 Years in Resected EGFR-Mutated Stage IB to IIIA NSCLC
3
PAPILLON: Frontline Amivantamab Plus Chemotherapy Yields 34.3-Month Median OS in EGFR Exon 20 Insertion–Positive NSCLC
4
Zidesamtinib Yields High Response Rates in TKI-Naive Advanced ROS1+ NSCLC
5